308 related articles for article (PubMed ID: 9815949)
1. High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a phase I clinical trial.
Stiff PJ; Bayer R; Tan S; Camarda M; Sosman J; Peace D; Kinch L; Rad N; Loutfi S
Clin Cancer Res; 1995 Dec; 1(12):1495-502. PubMed ID: 9815949
[TBL] [Abstract][Full Text] [Related]
2. Phase I-II trial of high-dose cyclophosphamide, carboplatin and autologous bone marrow or peripheral blood stem cell rescue.
Spitzer TR; Cirenza E; McAfee S; Foelber R; Zarzin J; Cahill R; Mazumder A
Bone Marrow Transplant; 1995 Apr; 15(4):537-42. PubMed ID: 7655378
[TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
4. A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma.
Weaver CH; Greco FA; Hainsworth JD; Zhen B; Baldwin P; Wittlin F; Lewis M; West WH; Schwartzberg L; Buckner CD
Bone Marrow Transplant; 1997 Nov; 20(10):847-53. PubMed ID: 9404925
[TBL] [Abstract][Full Text] [Related]
5. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; Demetri G; Levine J; Warren D; Arthur T; Reich E; Wheele C; Frei E; Ayash L
Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174
[TBL] [Abstract][Full Text] [Related]
6. High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors.
Mulder PO; Sleijfer DT; Willemse PH; de Vries EG; Uges DR; Mulder NH
Cancer Res; 1989 Aug; 49(16):4654-8. PubMed ID: 2545349
[TBL] [Abstract][Full Text] [Related]
7. Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study.
Chambers SK; Davis CA; Schwartz PE; Kohorn EI; Chambers JT
Clin Cancer Res; 1996 Oct; 2(10):1693-7. PubMed ID: 9816118
[TBL] [Abstract][Full Text] [Related]
8. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies.
Demirer T; Ilhan O; Mandel NM; Arat M; Günel N; Celebi H; Ustün C; Akan H; Demirer S; Aydintuğ S; Uysal A; Koç H
Bone Marrow Transplant; 2000 Apr; 25(7):697-703. PubMed ID: 10745253
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients.
Chambers SK; Davis CA; Chambers JT; Schwartz PE; Lorber MI; Hschumacher RE
Clin Cancer Res; 1996 Oct; 2(10):1699-704. PubMed ID: 9816119
[TBL] [Abstract][Full Text] [Related]
10. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
11. High-dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation for the treatment of advanced malignancies: a phase I study.
Saez RA; Slease RB; Strnad C; Selby GB; Confer DL; Epstein RB
Bone Marrow Transplant; 1995 Oct; 16(4):507-14. PubMed ID: 8528165
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer.
Gisselbrecht C; Extra JM; Lotz JP; Devaux Y; Janvier M; Peny AM; Guillevin L; Bremond D; Delain M; Herbrecht R; Lepage E; Maraninchi D
Bone Marrow Transplant; 1996 Nov; 18(5):857-63. PubMed ID: 8932837
[TBL] [Abstract][Full Text] [Related]
13. High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II study.
Toh HC; McAfee SL; Sackstein R; Multani P; Cox BF; Garcia-Carbonero R; Colby C; Spitzer TR
Bone Marrow Transplant; 2000 Jan; 25(1):19-24. PubMed ID: 10654009
[TBL] [Abstract][Full Text] [Related]
14. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P
Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670
[TBL] [Abstract][Full Text] [Related]
15. Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities.
Fields KK; Elfenbein GJ; Perkins JB; Hiemenz JW; Janssen WE; Zorsky PE; Ballester OF; Kronish LE; Foody MC
Semin Oncol; 1993 Oct; 20(5 Suppl 6):59-66. PubMed ID: 8211217
[TBL] [Abstract][Full Text] [Related]
16. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
Antman K; Eder JP; Elias A; Shea T; Peters WP; Andersen J; Schryber S; Henner WD; Finberg R; Wilmore D
Cancer Treat Rep; 1987 Feb; 71(2):119-25. PubMed ID: 3542208
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by short-course cyclosporin A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemia.
Bassan R; Lerede T; Borleri G; Chiodini B; Rossi A; Buelli M; Rambaldi A; Viero P; Barbui T
Haematologica; 2002 Mar; 87(3):257-63. PubMed ID: 11869937
[TBL] [Abstract][Full Text] [Related]
18. [A study to overcome drug resistance using high-dose chemotherapy with autologous bone marrow transplantation].
Mukaiyama T; Ogawa M; Horikoshi N; Inoue K; Fukutani H; Tabata M; Hirano A; Mizunuma N; Itami S
Gan To Kagaku Ryoho; 1989 May; 16(5):2013-8. PubMed ID: 2471462
[TBL] [Abstract][Full Text] [Related]
19. Tandem high-dose chemotherapy with ifosfamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma.
Lotz JP; Bouleuc C; André T; Touboul E; Macovei C; Hannoun L; Lefranc JP; Houry S; Uzan S; Izrael V
Cancer; 1996 Jun; 77(12):2550-9. PubMed ID: 8640705
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]